Indivior PLC (LON:INDV)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 1.23B |
| Revenue (ttm) | 905.57M |
| Net Income (ttm) | -47.99M |
| Shares Out | 124.77M |
| EPS (ttm) | -0.37 |
| PE Ratio | n/a |
| Forward PE | 10.87 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 203,819 |
| Average Volume | 347,018 |
| Open | 1,003.00 |
| Previous Close | 1,008.00 |
| Day's Range | 975.50 - 1,003.00 |
| 52-Week Range | 548.71 - 1,340.00 |
| Beta | 0.25 |
| RSI | 52.98 |
| Earnings Date | Jul 31, 2025 |
About Indivior
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX T... [Read more]
News
Indivior Appoints Tony Kingsley to the Board of Directors
RICHMOND, Va. , June 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Tony Kingsley to the Board of Directors as an Independent Non-Executive Director, eff...
Indivior Presents New Data at CPDD Demonstrating that High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl Users
A post-hoc analysis demonstrates that buprenorphine exposure with 300 mg SUBLOCADE® (buprenorphine extended-release) may improve treatment outcomes among opioid use disorder (OUD) patients with heavy ...
Drugmaker Invidior to abandon London listing amid exodus of companies
Firm behind opioid addiction treatment drugs quits London Stock Exchange after moving primary to US last year Business live – latest updates The drugmaker Indivior has become the latest company to aba...
Indivior to delist from London Stock Exchange, maintain primary listing on Nasdaq
Drug maker Indivior to abandon London stock market for the US
Indivior’s exit comes after the company moved its primary listing to the US’s Nasdaq index last year.
Drug maker Indivior joins the flight from London share listings
Pharmaceuticals company said most of its product sales and shareholders are US based
Indivior to delist from London Stock Exchange, maintain Nasdaq listing
Pharma firm Indivior said on Monday it will cancel its secondary listing on the London Stock Exchange, effective July 25, maintaining its primary listing on the Nasdaq to reduce costs and better align...
UK Stock Market News: Vodafone, Indivior, ME Group
Vodafone announces completion of Three deal, Indivior to cancel London listing, focus on NY, laundry performance cycles up at ME Group
Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained
SLOUGH, England and RICHMOND, Va. , June 2, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its intention to cancel: (i) the secondary listing of the Company's Ordinary Shares ("O...
Indivior Announces Patrick Barry as Chief Commercial Officer
Seasoned commercial executive with more than 30 years of pharmaceutical experience RICHMOND, Va. , May 27, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced the appointment of Patri...
Indivior to Participate in Upcoming Investor Events
RICHMOND, Va. , May 13, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ/LSE: INDV) today announced that it will participate in the following investor events: Jefferies Global Healthcare Conference – New Yor...
New Study Highlights Monthly SUBLOCADE® as a Potential Treatment Option for Opioid Use Disorder During and After Pregnancy
SUBLOCADE use during pregnancy showed no increased risk of birth defects, miscarriage, or maternal complications compared to general population rates RICHMOND, Va., May 1, 2025 /PRNewswire/ -- Indivio...
Indivior: Trying To Break Addiction
Indivior PLC’s recovery hinges on Sublocade’s momentum and market trends, though risks persist in litigation and earnings. Find out why INDV stock is a hold.
Indivior (INDV) Q1 2025 Earnings Call
Indivior signals 2025 SUBLOCADE net revenue guidance of $725M-$765M amid expanded investments
Indivior PLC (INDV) Q1 2025 Earnings Conference Call Transcript
Indivior PLC (NASDAQ:INDV) Q1 2025 Earnings Conference Call April 24, 2025 8:00 AM ETCompany ParticipantsJason Thompson - Head, IRMark Crossley - CEORyan...
Indivior Announces Q1 2025 Financial Results
SLOUGH, United Kingdom and RICHMOND, Va. , April 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending March 31, 2025.
A Look at Indivior's Upcoming Earnings Report
Indivior (NASDAQ: INDV) is set to give its latest quarterly earnings report on Thursday, 2025-04-24. Here's what investors need to know before the announcement. Analysts estimate that Indivior will r...
Decoding Indivior PLC (INDV): A Strategic SWOT Insight
Decoding Indivior PLC (INDV): A Strategic SWOT Insight
Two Seas Capital LP Reduces Stake in Indivior PLC
Two Seas Capital LP Reduces Stake in Indivior PLC
Indivior Announces Further Changes to Board of Directors
RICHMOND, Va. , March 4, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ / LSE: INDV) ("Indivior" or the "Company") today announced that, further to the announcement on December 17, 2024 of certain Director...
UK's Indivior appoints Joe Ciaffoni as CEO
British drugmaker Indivior on Thursday said it appointed Joe Ciaffoni as its new CEO, replacing current boss Mark Crossley.
Indivior Announces Joseph Ciaffoni Appointed Chief Executive Officer
RICHMOND, Va. , Feb. 27, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) has appointed Joe Ciaffoni, currently an Independent Non-Executive Director of the Company, as Chief Executive Officer.
Indivior gets FDA approval for label changes for Sublocade injection
Indivior Announces FDA Approval of Label Changes for SUBLOCADE® (buprenorphine extended-release) Injection
Rapid Initiation Protocol Reduces Time to Treatment with SUBLOCADE ® From One Week to One Hour, A Significant Advancement in the Treatment of Moderate to Severe Opioid Use Disorder (OUD) RICHMOND, Va....